WO2010095881A2 - 표적 선택적 세포/조직 투과기능 활성을 가지는 펩타이드 및 그 용도 - Google Patents
표적 선택적 세포/조직 투과기능 활성을 가지는 펩타이드 및 그 용도 Download PDFInfo
- Publication number
- WO2010095881A2 WO2010095881A2 PCT/KR2010/001033 KR2010001033W WO2010095881A2 WO 2010095881 A2 WO2010095881 A2 WO 2010095881A2 KR 2010001033 W KR2010001033 W KR 2010001033W WO 2010095881 A2 WO2010095881 A2 WO 2010095881A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- peptide
- target
- cell
- tissue
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 77
- 150000001875 compounds Chemical class 0.000 title abstract description 7
- 230000005945 translocation Effects 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 73
- 229940079593 drug Drugs 0.000 claims abstract description 71
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 70
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 64
- 230000000873 masking effect Effects 0.000 claims abstract description 19
- 125000006850 spacer group Chemical group 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 102000004190 Enzymes Human genes 0.000 claims abstract description 15
- 108090000790 Enzymes Proteins 0.000 claims abstract description 15
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 6
- 230000007017 scission Effects 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 142
- 210000001519 tissue Anatomy 0.000 claims description 81
- 235000018102 proteins Nutrition 0.000 claims description 63
- 230000000149 penetrating effect Effects 0.000 claims description 39
- 235000001014 amino acid Nutrition 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 239000002245 particle Substances 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- -1 anionic amino acid Chemical class 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 102100038298 Kallikrein-14 Human genes 0.000 claims description 8
- 230000001093 anti-cancer Effects 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 108700031308 Antennapedia Homeodomain Proteins 0.000 claims description 6
- 101710115806 Kallikrein-14 Proteins 0.000 claims description 6
- 102000007327 Protamines Human genes 0.000 claims description 6
- 108010007568 Protamines Proteins 0.000 claims description 6
- 229940048914 protamine Drugs 0.000 claims description 6
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- 108020004459 Small interfering RNA Proteins 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 claims description 4
- OYRSKXCXEFLTEY-UHFFFAOYSA-N 1-[2-[2-[2-[2-(2,5-dioxopyrrol-1-yl)ethoxy]ethoxy]ethoxy]ethyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CCOCCOCCOCCN1C(=O)C=CC1=O OYRSKXCXEFLTEY-UHFFFAOYSA-N 0.000 claims description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 4
- 102000001301 EGF receptor Human genes 0.000 claims description 4
- 108060006698 EGF receptor Proteins 0.000 claims description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 102000015617 Janus Kinases Human genes 0.000 claims description 4
- 108010024121 Janus Kinases Proteins 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 102000005741 Metalloproteases Human genes 0.000 claims description 4
- 108010006035 Metalloproteases Proteins 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 208000004736 B-Cell Leukemia Diseases 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
- 229940078581 Bone resorption inhibitor Drugs 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- 108091007960 PI3Ks Proteins 0.000 claims description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 3
- 108010039918 Polylysine Proteins 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 3
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 claims description 2
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 claims description 2
- JCZNWTFQAZEOSZ-AWRGLXIESA-N (2s)-6-amino-n-[(2s)-2-[[(2r)-2-amino-3-methylbutanoyl]amino]-4-methylpentanoyl]-2-[(4-methyl-2-oxochromen-7-yl)amino]hexanamide Chemical compound CC1=CC(=O)OC2=CC(N[C@@H](CCCCN)C(=O)NC(=O)[C@@H](NC(=O)[C@H](N)C(C)C)CC(C)C)=CC=C21 JCZNWTFQAZEOSZ-AWRGLXIESA-N 0.000 claims description 2
- WXXSHAKLDCERGU-UHFFFAOYSA-N 1-[4-(2,5-dioxopyrrol-1-yl)butyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CCCCN1C(=O)C=CC1=O WXXSHAKLDCERGU-UHFFFAOYSA-N 0.000 claims description 2
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 claims description 2
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims description 2
- 101710192266 Tegument protein VP22 Proteins 0.000 claims description 2
- 102100031013 Transgelin Human genes 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 2
- 108010011110 polyarginine Proteins 0.000 claims description 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 2
- 108010071226 valyl-leucyl-lysyl-7-amino-4-methylcoumarin Proteins 0.000 claims description 2
- 108010043655 penetratin Proteins 0.000 claims 2
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 108091012583 BCL2 Proteins 0.000 claims 1
- 239000004971 Cross linker Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 12
- 238000003745 diagnosis Methods 0.000 abstract description 9
- 238000009826 distribution Methods 0.000 abstract description 2
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 230000032258 transport Effects 0.000 description 31
- 210000004881 tumor cell Anatomy 0.000 description 24
- 238000011282 treatment Methods 0.000 description 19
- 230000035699 permeability Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 8
- 239000003431 cross linking reagent Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000605520 Homo sapiens Kallikrein-14 Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000255348 Drosophila sp. (in: Insecta) Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 101800000135 N-terminal protein Proteins 0.000 description 1
- 101800001452 P1 proteinase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 108010082406 peptide permease Proteins 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Definitions
- the present invention relates to target selective cell / tissue penetrating peptides and uses thereof, and more particularly target selective cell / tissue penetrating functionalities that specifically add drugs or drug-containing particles only to target cells / tissues by adding selectivity. It relates to a peptide and a complex of the drug or drug-containing particles thereof.
- PTD protein transduction domain
- HAV-1 human immunodeficiency virus-1
- YGRKKRRQRRR transmembrane cell membranes consisting of a portion of the 47th to 57th amino acid sequence (YGRKKRRQRRR), in which the positively charged amino acids are concentrated, rather than the complete form of 86 amino acids.
- PTD effect as PTD
- peptides having amino acid sequences 267 to 300 of the VP22 protein of HSV-1 (herpes simplex virus type 1) (Elliott, G. et al., Cell , 88: 223, 1997), peptides having amino acid sequences 84-92 of the UL-56 protein of HSV-2 (GeneBank code: D1047 [gi: 221784]) and antennapedia of the genus Drosophila sp. , ANTP) peptides (Schwarze, SR et al., Trends. Pharmacol.
- LMWP low molecular weight protamine
- the present inventors have attempted to minimize the side effects or problems of low image quality due to the nonspecific distribution of a substance for diagnosis or treatment of an existing disease, and to develop a method for effectively and effectively delivering a substance for diagnosis or disease treatment only to target cells.
- a target selective cell / tissue permeable peptide consisting of a spacer having a protein transport domain (PTD) -target histase-specific cleavage site and a masking domain which ionically binds to the protein transport domain (PTD)
- PTD protein transport domain
- Another object of the present invention is to provide a pharmaceutical composition for diagnosing and treating diseases such as cancer and inflammation, including the target selective cell / tissue penetrating functional peptide-drug complex.
- the present invention provides a target activated cell / tissue translocation peptide for Impermeable Compound Strategy (TACYICS), including:
- PTD protein transport domain
- a spacer which connects the protein transport domain (PTD) and the masking domain and has a target cell / tissue enzyme specific cleavage site.
- the protein transport domain is composed of amino acids of D-type or L-type, and may include any one or more amino acids selected from the group consisting of arginine, lysine and histidine in an amount of 70-80%. Can be.
- the masking domain ion-bonding with the protein transport domain is composed of D-type or L-type amino acids, it may be characterized in that it comprises an anionic amino acid in a content of 70 ⁇ 100% have.
- the anionic amino acid may include glutamic acid or aspartic acid, preferably, the masking domain may be composed of 4 to 8 amino acids.
- the spacer is any one enzyme selected from the group consisting of prostate cancer surface enzyme, kallikrein 14 (Kallikrein 14, KLK14), catepsin (Cathepsin) and matrix metalloprotease (MMP) It can be characterized by having a site
- the present invention also provides a target selective cell / tissue penetrating peptide-drug complex, characterized in that the target selective cell / tissue penetrating peptide and drug or drug-containing particles are combined.
- a drug or a drug-containing particle may be coupled to a protein transport domain (PTD) of the target selective cell / tissue permeable peptide, preferably the protein transport domain (PTD) and the drug or Drug-containing particles can be linked to cysteine.
- PTD protein transport domain
- the drug is an antisense oligonucleotide targeting RNA of an anticancer agent, an anticancer protein, an anti-inflammatory agent, an anti-inflammatory protein, an immune enhancing protein, an bone resorption inhibitor, a tumor or an inflammatory disease protein, and an RNA of a tumor or inflammatory disease protein. It may be characterized in that the selected from the group consisting of siRNA as a target.
- the present invention also provides a pharmaceutical composition for diagnosing and treating a disease comprising the target selective cell / tissue permeable peptide-drug complex. That is, it can provide a pharmaceutical composition for treating cancer diseases.
- the present invention also provides a method for treating a cancer disease, characterized in that by administering the target selective cell / tissue permeable peptide-drug complex.
- the present invention also provides a use of the target selective cell / tissue permeable peptide-drug complex for the treatment of cancer.
- FIG. 1 is a schematic of the mechanism of a target selective cell / tissue permeable peptide-drug complex according to the present invention.
- FIG. 2 is a photograph of fluorescence of normal cell lines (a) and tumor cell lines (b) measured by FACS after fluorescence-labeled target selective cell / tissue penetrating functional peptide treatment.
- Figure 3 is a photograph of the tumor cell line group (a) and normal cell line group (b) after fluorescence-labeled target selective cell / tissue penetrating functional peptide treatment observed by confocal microscopy.
- Figure 4 is a photograph of the fluorescence of normal cell line (a) and tumor cell line (b) after treatment with the target selective cell / tissue penetrating functional peptide-gelonin complex observed by confocal microscopy.
- FIG. 5 is a photograph of fluorescence of normal cell lines (a) and tumor cell lines (b) measured by FACS after treatment with target selective cell / tissue penetrating peptide-gelonin complexes.
- Figure 6 is a graph showing the cell survival rate in the normal cell group (1) and tumor cell group (2 and 3) according to the target selective cell / tissue penetrating functional peptide-gelonin complex treatment concentration.
- 'protein transport domain refers to a permeable peptide that can permeate a drug or drug-containing particles into the cytoplasm or nucleus of a cell. This means that covalent bonds with oligonucleotides, peptides, proteins, oligosaccharides, polysaccharides, or nanoparticles can introduce these substances into cells without requiring additional receptors, carriers, or energy.
- target cell / tissue refers to cells and tissues to which drugs or drug-containing particles are delivered by a target selective cell / tissue penetrating functional peptide, and refers to cells in or outside the body.
- target cells / tissues are meant to include cells in the body, ie cells constituting organs or tissues of living animals or humans, or microorganisms found in living animals or humans.
- target cells / tissues are meant to include extracellular cells, ie cultured animal cells, human cells or microorganisms.
- the present invention relates to a target activated cell / tissue translocation peptide for impermeable compound strategy (TACYICS), comprising:
- PTD protein transport domain
- a spacer which connects the protein transport domain (PTD) and the masking domain and has a target cell / tissue enzyme specific cleavage site.
- the present invention relates to a cell / tissue delivery technique for preparing a target selective cell / tissue penetrating functional peptide and allowing drug-containing particles such as drugs or drug-containing nanomagnetic particles to penetrate only into target cells / tissues.
- drug-containing particles such as drugs or drug-containing nanomagnetic particles
- FIG. 1 the drug or drug-containing nanoparticles to be introduced are chemically bound and then treated in vivo and in vitro in an aqueous solution, thereby exhibiting no permeability in non-target cells. And permeate only into the target cell. In other words, the cell is directly introduced into the cell without endocytosis.
- the target selective cell / tissue penetrating peptide according to the present invention can be prepared using a peptide synthesizing apparatus by chemical synthesis, and the spacer and masking domains are sequentially arranged at the C terminal of the protein transport domain (PTD) having intracellular penetrating function.
- the compound can be synthesized in the order of the N terminal-protein transport domain-spacer-masking domain-C terminus, and also in the order of the N terminal-masking domain-spacer-protein transport domain-C terminus. .
- the protein transport domain may include 70 to 80% of any one or more amino acids selected from the group consisting of arginine, lysine and histidine.
- the amino acid constituting the protein transport domain (PTD) can be L-type or D-type in consideration of stability in the body.
- Protein transport domains (PTDs) having intracellular permeability include 70 to 80 cationic protein transport domain peptides other than LMWP (SEQ ID NO: 1: VSRRRRRRGGRRRR), a transport domain found by the inventors, ie arginine, lysine or histidine.
- Peptides containing at least% may be used, preferably TAT (SEQ ID NO: 2: YGRKKRRQRRR), Pentratratin (SEQ ID NO: 3: RQIKIWFQNRRMKWKK), polyarginine (SEQ ID NO: 4: RRRRRRR), polylysine (polylysine) (SEQ ID NO: 5: KKKKKKKK), protamine fragments and antennapedia (ANTP) may be used, and other peptides or peptide analogs other than those described above may be used as long as they can penetrate the cell membrane. .
- the masking domain ion-bonding with the protein transport domain may be characterized in that it comprises an anionic amino acid in a content of 70 ⁇ 100%.
- the amino acid constituting the masking domain can be L-type or D-type in consideration of stability in the body.
- the anionic amino acid may include glutamic acid or aspartic acid, preferably, the masking domain may be composed of 4 to 8 amino acids.
- the spacer is any one enzyme selected from the group consisting of prostate cancer surface enzyme, kallikrein 14 (Kallikrein 14, KLK14), catepsin (Cathepsin) and matrix metalloprotease (MMP) It may be characterized by having a site that is cleaved by, wherein the spacer is SEQ ID NO: 6 (CHSSKLQG), SEQ ID NO: 7 (LRLSSYYM), SEQ ID NO: 8 (SSQPWQ), SEQ ID NO: 9 (RRFLCG), SEQ ID NO: 10 ( THDNDL), SEQ ID NO: 11 (VRPIE), SEQ ID NO: 12 (VSGWGT), SEQ ID NO: 13 (YPAS), SEQ ID NO: 14 (TITPGM), SEQ ID NO: 15 (QGRAMC), SEQ ID NO: 16 (GPRAMC), SEQ ID NO: 17 (QRRAMC ), SEQ ID NO: 18 (GGRAMC), SEQ ID NO: 19 (VLKAMC), SEQ ID NO:
- the present invention relates to a target selective cell / tissue penetrating peptide-drug complex, characterized in that the target selective cell / tissue penetrating peptide is combined with a drug or drug-containing particle.
- the target selective cell / tissue penetrating peptide is covalently bound to a drug or drug-containing particle to provide a target selective cell / tissue penetrating peptide-drug complex, the protein transport domain (PTD) of the target selective cell / tissue penetrating peptide.
- Drugs or drug-containing nanoparticles may be covalently bonded to the N- or C-terminus, and preferably, cysteine is additionally attached to the distal end of the protein transport domain (PTD).
- the complex may be made by inducing a chemical bond using a crosslinking agent.
- a crosslinking agent When chemical bonds are induced using a crosslinking agent, complexes formed by the crosslinking agent are easily formed because each of the free amino groups is provided at the N-terminus of the protein transport domain (PTD) peptide, that is, the protein transport domain (PTD).
- the crosslinking agent that can be used in the present invention is 1,4-bis-maleimidobutane (BMB), 1,11-bis-maleimidotetraethyleneglycol (1,11-bis-maleimidotetraethyleneglycol, BM [PEO] 4), 1-ethyl-3- [3-dimethyl aminopropyl] carbodiimide hydrochloride (1-ethyl-3- [3-dimethyl aminopropyl] carbodiimide hydrochloride (EDC), succinimidyl-4- [ N-maleimidomethylcyclohexane-1-carboxy- [6-amidocaproate]] (succinimidyl-4- [N-maleimidomethylcyclohexane-1-carboxy- [6-amidocaproate]], SMCC) and its sulfonates -SMCC), succimidyl 6- [3- (2-pyridyldithio) -lopionamido
- the drug may be dissociated from the cell-penetrating peptide in the cell by a reductase or the like present in the cell.
- the drug includes an anticancer agent, an anti-inflammatory agent, a bone resorption inhibitor, an anticancer protein, an anti-inflammatory protein, an immunopotentiating protein, an anti-cancer and anti-inflammatory siRNA, an oligonucleotide, and nanomagnetic particles containing them.
- siRNA refers to RNA silencing expression of target RNA.
- Target RNA is a mRNA transcribed from a disease-causing gene, in particular, a tumor or inflammation-causing gene.
- the cancer-causing gene is a vascular endothelial growth factor (vascular endothelial growth factor (VEGF) gene, but is not limited thereto.
- VEGF vascular endothelial growth factor
- the tumor or inflammatory disease protein is vascular endothelial growth factor (VEGF), B-cell Leukemia / lymphoma 2 (BCL2), epidermal growth factor receptor (epidermal growth factor receptor) factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), Janus kinase (JAN) and phosphatidylinositol-3-kinase / Akt kinase (phosphatidylinositol-3-kinase / Akt) kinase, PI3-K / AKT).
- VEGF vascular endothelial growth factor
- BCL2 B-cell Leukemia / lymphoma 2
- EGFR epidermal growth factor receptor (epidermal growth factor receptor) factor receptor
- HER2 human epidermal growth factor receptor 2
- JAN Janus kinase
- phosphatidylinositol-3-kinase / Akt kinase
- the present invention relates to a pharmaceutical composition for diagnosing and treating a disease comprising the target selective cell / tissue permeable peptide-drug complex. That is, it can be provided as a pharmaceutical composition for treating cancer diseases.
- the target selective cell / tissue permeable peptides according to the present invention were labeled with the fluorescent marker FITC and applied to normal cells and tumor cells.
- the fluorescence in tumor cells was increased and the fluorescence in normal cells was the same as before application. It was confirmed. This is because the spacer is degraded by the enzyme on the surface of the tumor cell, and thus, the fluorescently labeled target selective cell / tissue penetrating functional peptide is dissociated and penetrated into the tumor cell.
- the peptide's permeability was not exerted.
- binding the tumor suppressor protein to the terminal of the peptide did not affect the cell growth of normal cells, while suppressing the growth of tumor cells.
- MTT assay was performed to determine the effective inhibitory concentration (IC50) of the target selective cell / tissue penetrating functional peptide-drug according to the present invention, and showed cytotoxicity even at a low concentration of 5 ⁇ 10 ⁇ 9 M.
- the pharmaceutical composition of the present invention may be administered with a pharmaceutically acceptable carrier, and during oral administration, a binder, a suspending agent, a disintegrant, an excipient, a solubilizer, a dispersant, a stabilizer, a suspending agent, a coloring agent, a flavoring agent, etc. may be used.
- a pharmaceutically acceptable carrier such as a pharmaceutically acceptable triglyceride, a pharmaceutically acceptable sulfate, etc.
- a pharmaceutically acceptable carrier such as described above.
- oral administration in the case of oral administration, it may be prepared in the form of tablets, troches, capsules, elesir, suspensions, syrups, wafers, etc., and in the case of injections, may be prepared in unit dosage ampoules or multiple dosage forms.
- composition of the present invention may be administered in a therapeutically or prophylactically effective amount. Dosage may vary depending on a variety of factors, including the type and severity of the patient, age, sex, weight, sensitivity to the drug, type of current treatment, method of administration, target cells, and can be readily determined by those skilled in the art. Can be.
- the composition of the present invention may be administered in combination with a conventional therapeutic agent and may be administered sequentially or simultaneously with the conventional therapeutic agent. It may also be single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, and can be easily determined by those skilled in the art.
- the term “administration” means introducing a predetermined substance into a patient in any suitable manner and the route of administration of the pharmaceutical composition of the present invention may be administered via any general route as long as it can reach the desired tissue.
- the pharmaceutical composition may be administered by any device that allows the active material to migrate to the target cell.
- gelonin an anticancer protein as a drug
- other anticancer proteins, antisense oligonucleotides of cancer-causing genes, siRNA, and the like and particles containing them are similar in tumor treatment.
- the same effects can be obtained, and anti-inflammatory effects using anti-inflammatory substances, anti-inflammatory proteins, etc. as drugs in relation to anti-inflammatory treatments will be apparent to those skilled in the art.
- Target selective cells / tissues using peptide synthesizers to contain EEEEEEE (SEQ ID NO: 27) as a masking domain, PLGLAG (SEQ ID NO: 25), which is a sequence degraded in MMP as a spacer, and LMWP as PTD, in order from the N terminus Permeable peptides were synthesized by F-moc solid phase chemical synthesis.
- the synthesized peptide sequence was cleaved from the resin, washed, lyophilized and separated and purified by liquid chromatography. The purified peptide was confirmed molecular weight using MALDI analysis.
- the target selective cell / tissue penetrating functional peptide prepared in Example 1 contains cysteine and there is a free-sulfhydryl group, it is used as a chemical crosslinking agent to chemically react with the anticancer protein Gelonin. Binding was induced.
- the modification of the surface of the gelonin was made in the form of attaching a thiol group to the surface carboxyl group. After 10 minutes of peptide-SH per 1 particle surface-SH of the molecule was reacted at 4 ° C for 12 hours, the unbound molecules were filtered through ultrafiltration, and then lyophilized to target selective cells / tissues. Permeable peptide-gelonin complex was obtained.
- Example 3 Tumor intracellular permeability of target selective cell / tissue permeable peptides
- Example 2 To test the cell selective permeability of the target selective cell / tissue permeable peptide prepared in Example 1, fluorescently labeled with FITC at the C terminus of the prepared peptide, these were normal cell line (ATCC) and tumor cell line (CT-26, KCLB). (0909) Korea cell line bank).
- a represents the fluorescence of the normal cell line
- b represents the fluorescence of the tumor cell line.
- the experimental results indicate that the target selective cell / tissue permeability was degraded by the action of the enzyme, while the spacer having the PLGLAG peptide sequence (SEQ ID NO: 25), which is a cleavage site specific for tumor cell surface enzyme (MMP), on the tumor cell surface.
- the masking domain (EEEEEEE: SEQ ID NO: 27), which ionizes and covers the protein transport domain (PTD) of the peptide, dissociates and the LMWP
- the protein transport domain (PTD) is smoothly introduced into the cells, whereas in normal cells, it is an enzyme spacer. No degradation occurred, indicating that introduction was inhibited even when the same peptide was treated.
- the target selective cell / tissue permeable peptide-anticancer protein complex prepared in Example 2 was inoculated into a normal cell line (ATCC) and a tumor cell line (CT-26, KCLB (Korea cell line bank) 80009).
- CT-26 normal cell line
- KCLB Kirea cell line bank 80009
- the cells were stained with Hoechst 33342 (5 ⁇ g / ml), which stains the cell nuclei, and the cells were fixed with 10% neutral formalin solution.
- the spacer was decomposed by the action of the enzyme on the surface of the tumor cell, and the masking domain, which was ion-bonded and masked the LMWP, which is the protein transport domain (PTD) of the target selective cell / tissue penetrating functional peptide, was dissociated and the protein While the transport domain (PTD) was smoothly introduced into the cells, spacer degradation by enzymes did not occur in normal cells, indicating that introduction was inhibited even when the same peptide was treated.
- the LMWP which is the protein transport domain (PTD) of the target selective cell / tissue penetrating functional peptide
- MTT assay is a test that utilizes the ability of the mitochondria to reduce the yellow water-soluble substrate MTT tetrazolium to a blue-violet, water-insoluble MTT formazan by dehydrogenase action.
- the normal cell group does not exhibit cytotoxicity by the applied complex, whereas the tumor cell group showed significant cytotoxicity when the peptide complex was treated, the effective inhibitory concentration (IC50) is approximately It was measured at 5 x 10 -9 M.
- IC50 the effective inhibitory concentration
- 1 indicates the cell growth in the normal cell group
- 2 and 3 shows the cell growth in the tumor cell line (CT-26) as a result of two experiments.
- the experimental results indicate that the activity of the penetrating functional peptide is selectively restored in the tumor cell group, and thus the penetrating peptide-anticancer protein complex is introduced into the cell to exhibit an effective anticancer force even at low concentrations.
- the target selective cell / tissue permeable peptide-drug complex according to the present invention shows high safety by breaking away from the existing non-specific and non-selective peptide transporter, and the diagnosis and drug treatment through optimal target orientation. Maximize the effectiveness of the therapy and minimize side effects.
- the present invention can provide innovative disease diagnosis and treatment technology by providing a pharmaceutical composition for diagnosing and treating a disease, including a target-selective cell / tissue permeable peptide-drug complex having target cell specific permeability.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (15)
- 다음을 포함하는 표적 선택적 세포/조직 투과성 펩타이드(TACTICS):(a) 단백질 수송 도메인(PTD);(b) 상기 단백질 수송 도메인(PTD)과 이온결합하는 마스킹 도메인; 및(c) 상기 단백질 수송 도메인(PTD)과 마스킹 도메인을 연결하며, 표적세포/조직 효소 특이적인 절단부위를 가지는 스페이서(spacer).
- 제1항에 있어서, 상기 단백질 수송 도메인(PTD)은 D-형 또는 L-형의 아미노산으로 구성되며, 아르기닌, 라이신 및 히스티딘으로 구성된 군에서 선택된 어느 하나 이상의 아미노산을 70~80%의 함량으로 포함하는 것을 특징으로 하는 표적 선택적 세포/조직 투과기능성 펩타이드.
- 제1항에 있어서, 상기 단백질 수송 도메인(PTD)은 저분자 프로타민(Low molecular weight protamine, LMWP), TAT, 페너트라틴(Penetratin), 폴리아르기닌(polyarginine), 폴리라이신(polylysine), 프로타민(protamine)절편, VP22 펩타이드, UL-56 펩타이드, mph-1-btm 및 안테나페디아(Antennapedia, ANTP)로 구성된 군에서 선택된 어느 하나의 펩타이드 또는 이의 유사체인 것을 특징으로 하는 표적 선택적 세포/조직 투과기능성 펩타이드.
- 제1항에 있어서, 상기 단백질 수송 도메인(PTD)과 이온결합하는 마스킹 도메인은 D-형 또는 L-형의 아미노산으로 구성되며, 음이온성 아미노산을 70~100%의 함량으로 포함하는 것을 특징으로 하는 표적 선택적 세포/조직 투과기능성 펩타이드.
- 제4항에 있어서, 상기 음이온성 아미노산은 글루타민산 또는 아스파틱산을 포함하는 것을 특징으로 하는 표적 선택적 세포/조직 투과기능성 펩타이드.
- 제4항에 있어서, 상기 마스킹 도메인은 4~8개의 아미노산으로 구성되는 것을 특징으로 하는 표적 선택적 세포/조직 투과기능성 펩타이드.
- 제1항에 있어서, 상기 스페이서는 전립선암 표면효소, 칼리크레인 14(Kallikrein 14, KLK14), 카텝신(Cathepsin) 및 기질금속단백분해효소(matrix metalloprotease, MMP)로 구성된 군에서 선택된 어느 하나의 효소에 의해 절단되는 부위를 가지는 것을 특징으로 하는 표적 선택적 세포/조직 투과기능성 펩타이드.
- 제7항에 있어서, 상기 스페이서는 서열번호 6(CHSSKLQG), 서열번호 7(LRLSSYYM), 서열번호 8(SSQPWQ), 서열번호 9(RRFLCG), 서열번호 10(THDNDL), 서열번호 11(VRPIE), 서열번호 12(VSGWGT), 서열번호 13(YPAS), 서열번호 14(TITPGM), 서열번호 15(QGRAMC), 서열번호 16(GPRAMC), 서열번호 17(QRRAMC), 서열번호 18(GGRAMC), 서열번호 19(VLKAMC), 서열번호 20(LGRAMC), 서열번호 21(QARAMC), 서열번호 22(VPRAMC), 서열번호 23(PFRAMC), 서열번호 24(FSRAMC), 서열번호 25(PLGLAG) 및 서열번호 26(SGRSA)로 구성된 군에서 선택된 어느 하나의 서열을 포함하는 것을 특징으로 하는 표적 선택적 세포/조직 투과기능성 펩타이드.
- 제1항 내지 제8항 중 어느 한 항의 표적 선택적 세포/조직 투과기능성 펩타이드와 약물 또는 약물함유입자가 결합된 것을 특징으로 하는 표적 선택적 세포/조직 투과기능성 펩타이드-약물 복합체.
- 제9항에 있어서, 상기 표적 선택적 세포/조직 투과기능성 펩타이드의 단백질 수송 도메인(PTD)에 약물 또는 약물함유입자가 결합된 것을 특징으로 하는 표적 선택적 세포/조직 투과기능성 펩타이드-약물 복합체.
- 제10항에 있어서, 상기 단백질 수송 도메인(PTD)과 약물 또는 약물함유입자는 시스테인으로 연결된 것을 특징으로 하는 표적 선택적 세포/조직 투과기능성 펩타이드-약물 복합체.
- 제9항에 있어서, 상기 결합은 1,4-비스-말레이미도부탄 (1,4-bis-maleimidobutane, BMB), 1,11-비스-말레이미도테트라에틸렌글리콜 (1,11-bis-maleimidotetraethyleneglycol, BM[PEO]4), 1-에틸-3-[3-디메틸 아미노프로필] 카보디이미드 하이드로클로라이드(1-ethyl-3-[3-dimethyl aminopropyl] carbodiimide hydrochloride, EDC), 숙시니미딜-4-[N-말레이미도메틸시클로헥산-1-카복시-[6-아미도카프로에이트]](succinimidyl-4-[N-maleimidomethylcyclohexane-1-carboxy-[6-amidocaproate]], SMCC) 및 그의 설폰화염(sulfo-SMCC), 숙시미딜 6-[3-(2-피리딜디티오)-로피오나미도] 헥사노에이트](succimidyl 6-[3-(2-pyridyldithio)-ropionamido] hexanoate, SPDP) 및 그의 설폰화염(sulfo-SPDP), m-말레이미도벤조일-N-하이드로시숙시니미드 에스터(m-maleimidobenzoyl-N-hydroxysuccinimide ester, MBS) 및 그의 설폰화염(sulfo-MBS), 및 숙시미딜[4-(p-말레이미도페닐) 부틸레이트](succimidyl[4-(p-maleimidophenyl) butyrate], SMPB) 및 그의 설폰화염(sulfo-SMPB)로 구성된 군에서 선택된 어느 하나의 가교제에 의한 것임을 특징으로 하는 표적 선택적 세포/조직 투과기능성 펩타이드-약물 복합체.
- 제9항에 있어서, 상기 약물은 항암제, 항암성 단백질, 항염제, 항염 단백질, 면역증강단백질, 골흡수 억제제, 종양 또는 염증질환 단백질의 RNA를 타겟으로 하는 안티센스올리고뉴클레오티드 및 종양 또는 염증질환 단백질의 RNA를 타겟으로 하는 siRNA로 구성되는 군에서 선택된 것을 특징으로 하는 표적 선택적 세포/조직 투과기능성 펩타이드-약물 복합체.
- 제13항에 있어서, 상기 종양 또는 염증질환 단백질은 혈관 내피세포 성장인자(vascular endothelial growth factor, VEGF), B-cell 루케미아/림포마 2(B-cell leukemia/lymphoma 2, BCL2), 표피 성장인자 수용체(epidermal growth factor receptor, EGFR), 인간 표피 성장인자 수용체(human epidermal growth factor receptor 2, HER2), 야누스 카이네이즈(Janus kinase, JAN) 및 포스파티딜리노시톨-3-카이네이즈/Akt 카이네이즈(phosphatidylinositol-3-kinase/Akt kinase, PI3-K/AKT)로 구성된 군에서 선택된 것임을 특징으로 하는 표적 선택적 세포/조직 투과기능성 펩타이드-약물 복합체.
- 제13항의 표적 선택적 세포/조직 투과기능성 펩타이드-약물 복합체를 포함하는 암 질환의 치료용 약학적 조성물.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2753181A CA2753181C (en) | 2009-02-19 | 2010-02-19 | Target-activated cell/tissue penetrating peptide for delivery of impermeable compounds and use thereof |
MX2011008727A MX2011008727A (es) | 2009-02-19 | 2010-02-19 | Peptido penetrador de celulas/tejido, activado por el objetivo, para la distribucion de compuestos impermeables y uso de los mismos. |
US13/202,317 US8796219B2 (en) | 2009-02-19 | 2010-02-19 | Target-activated cell/tissue-penetrating peptide for delivery of impermeable compounds and use thereof |
EP10743956.4A EP2399939B1 (en) | 2009-02-19 | 2010-02-19 | Target activated cell/tissue translocation peptide for impermeable compound strategy, and uses thereof |
CN2010800154349A CN102369220A (zh) | 2009-02-19 | 2010-02-19 | 用于不渗透化合物策略的靶向激活的细胞/组织转位肽及其应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090013684A KR101095841B1 (ko) | 2009-02-19 | 2009-02-19 | 표적 선택적 세포/조직 투과기능 활성을 가지는 펩타이드 및 그 용도 |
KR10-2009-0013684 | 2009-02-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010095881A2 true WO2010095881A2 (ko) | 2010-08-26 |
WO2010095881A3 WO2010095881A3 (ko) | 2011-01-06 |
Family
ID=42634340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/001033 WO2010095881A2 (ko) | 2009-02-19 | 2010-02-19 | 표적 선택적 세포/조직 투과기능 활성을 가지는 펩타이드 및 그 용도 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8796219B2 (ko) |
EP (1) | EP2399939B1 (ko) |
KR (1) | KR101095841B1 (ko) |
CN (1) | CN102369220A (ko) |
CA (1) | CA2753181C (ko) |
MX (1) | MX2011008727A (ko) |
WO (1) | WO2010095881A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552929A (zh) * | 2010-12-30 | 2012-07-11 | 北京大学 | 通过修饰细胞穿透肽提高给药系统的靶向选择性的方法 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7985401B2 (en) | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
CA2770980A1 (en) | 2009-07-15 | 2011-01-20 | Roger Y. Tsien | Peptides whose uptake in cells is controllable |
EP2736533B1 (en) | 2011-07-29 | 2018-07-04 | Avelas Biosciences, Inc. | Selective delivery molecules and methods of use |
KR101456026B1 (ko) * | 2012-09-18 | 2014-11-04 | 서울대학교산학협력단 | 종양선택적 투과기능성을 가지는 펩타이드 및 그 용도 |
CN102993309B (zh) * | 2012-10-18 | 2014-12-03 | 武汉大学 | 一种人生长素融合蛋白TAT-hGH及其制备方法和应用 |
US10029017B2 (en) | 2013-01-29 | 2018-07-24 | The Regents Of The University Of California | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug |
US9782498B2 (en) | 2013-01-30 | 2017-10-10 | Avelas Biosciences, Inc. | Selective delivery molecules and methods of use |
TW201441249A (zh) * | 2013-04-03 | 2014-11-01 | Aliophtha Ag | 人工轉錄因子及其用於治療眼睛的不適應性傷口癒合之用途 |
TW201514202A (zh) | 2013-04-03 | 2015-04-16 | Aliophtha Ag | 經工程改造以克服內體捕獲之人工轉錄因子 |
US20160082119A1 (en) * | 2013-04-22 | 2016-03-24 | Avelas Biosciences, Inc. | Selective drug delivery compositions and methods of use |
WO2014197816A1 (en) * | 2013-06-06 | 2014-12-11 | Massachusetts Institute Of Technology | Stimulus responsive nanocomplexes and methods of use thereof |
KR101529634B1 (ko) * | 2013-08-28 | 2015-06-30 | 서울대학교산학협력단 | 역분화 유도를 위한 세포투과성 융합 단백질 및 그 용도 |
WO2015057009A1 (ko) | 2013-10-17 | 2015-04-23 | 서울대학교산학협력단 | 알파나선형 세포 투과 펩타이드 다합체, 이의 제조방법 및 그 용도 |
CN103784406A (zh) * | 2014-01-20 | 2014-05-14 | 同济大学 | 一种偶联穿膜肽和mmp酶切位点的纳米颗粒 |
US20170177834A1 (en) * | 2014-03-21 | 2017-06-22 | The Regents Of The University Of California | Nanomedicine optimization with feedback system control |
US10058595B2 (en) | 2014-05-15 | 2018-08-28 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising TNF-inhibiting antibodies |
WO2016050934A1 (en) * | 2014-10-02 | 2016-04-07 | Aliophtha Ag | Endosomal disentanglement of artificial transcription factors |
US10385380B2 (en) | 2014-10-02 | 2019-08-20 | The Regents Of The University Of California | Personalized protease assay to measure protease activity in neoplasms |
US10596259B2 (en) | 2015-05-20 | 2020-03-24 | The Regents Of The University Of California | Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof |
KR101647804B1 (ko) * | 2015-06-24 | 2016-08-11 | 한국과학기술연구원 | 신규 세포투과 펩타이드 및 이의 용도 |
KR102114842B1 (ko) | 2016-09-19 | 2020-05-27 | 주식회사 바이오에프디엔씨 | 세포 투과형 염기성섬유아세포성장인자를 함유하는 피부 생리활성 피부외용제 조성물 |
KR102114845B1 (ko) | 2016-09-19 | 2020-05-27 | 주식회사 바이오에프디엔씨 | 세포 투과형 혈관내피세포성장인자 융합 단백질을 함유하는 피부 생리활성 피부외용제 조성물 |
KR20190065178A (ko) * | 2017-12-01 | 2019-06-11 | 주식회사 굳티셀 | 탈모의 예방 또는 치료용 조성물 |
KR102068295B1 (ko) * | 2017-12-26 | 2020-01-20 | 한국화학연구원 | 암 과발현 효소의 기질로서 신규 지질-펩티드-고분자 컨쥬게이트가 함유된 암 미세환경 감응성 복합 약물전달시스템 |
CA3040645A1 (en) * | 2019-04-18 | 2020-10-18 | Feldan Bio Inc. | Peptide-based non-proteinaceous cargo delivery |
KR20220029800A (ko) | 2020-08-27 | 2022-03-10 | 주식회사 하울바이오 | 키메라 항원 수용체 단백질 및 이의 용도 |
CN114181315B (zh) * | 2020-09-14 | 2024-02-09 | 清华大学 | 一种内体逃逸肽及其应用 |
CN112451457A (zh) * | 2020-12-17 | 2021-03-09 | 王森阳 | 一种无刺激除痘隔离霜及其制备方法 |
KR20230164937A (ko) * | 2022-05-26 | 2023-12-05 | 주식회사 바이오셀트란 | 신규한 미백 펩타이드 및 이를 함유하는 화장료 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7431915B2 (en) * | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
GB0515115D0 (en) * | 2005-07-22 | 2005-08-31 | Isogenica Ltd | Peptide characterisation |
WO2007095152A2 (en) * | 2006-02-10 | 2007-08-23 | The Regents Of The University Of California | TRANSDUCIBLE DELIVERY OF sIRNA BY dsRNA BINDING DOMAIN FUSIONS TO PTD/CPPS |
-
2009
- 2009-02-19 KR KR1020090013684A patent/KR101095841B1/ko active IP Right Grant
-
2010
- 2010-02-19 CN CN2010800154349A patent/CN102369220A/zh active Pending
- 2010-02-19 US US13/202,317 patent/US8796219B2/en active Active
- 2010-02-19 CA CA2753181A patent/CA2753181C/en active Active
- 2010-02-19 MX MX2011008727A patent/MX2011008727A/es active IP Right Grant
- 2010-02-19 EP EP10743956.4A patent/EP2399939B1/en active Active
- 2010-02-19 WO PCT/KR2010/001033 patent/WO2010095881A2/ko active Application Filing
Non-Patent Citations (6)
Title |
---|
ELLIOTT G. ET AL., CELL, vol. 88, 1997, pages 223 - 233 |
FAWELL, S. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 664 |
LAUS, R. ET AL., NATURE. BIOTECHNOL., vol. 18, 2000, pages 1269 |
PARK, Y.J. ET AL., J. GENE. MED., vol. 700, 2003 |
SCHWARZE, S.R. ET AL., TRENDS. PHARMACOL. SCI., vol. 21, 2000, pages 45 |
See also references of EP2399939A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552929A (zh) * | 2010-12-30 | 2012-07-11 | 北京大学 | 通过修饰细胞穿透肽提高给药系统的靶向选择性的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102369220A (zh) | 2012-03-07 |
CA2753181A1 (en) | 2010-08-26 |
CA2753181C (en) | 2015-11-24 |
EP2399939B1 (en) | 2015-04-01 |
MX2011008727A (es) | 2011-11-18 |
KR20100094622A (ko) | 2010-08-27 |
EP2399939A4 (en) | 2013-08-28 |
US8796219B2 (en) | 2014-08-05 |
WO2010095881A3 (ko) | 2011-01-06 |
KR101095841B1 (ko) | 2011-12-21 |
US20120053129A1 (en) | 2012-03-01 |
EP2399939A2 (en) | 2011-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010095881A2 (ko) | 표적 선택적 세포/조직 투과기능 활성을 가지는 펩타이드 및 그 용도 | |
US10287581B2 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
EP2928907B1 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
Martín et al. | Design, synthesis and characterization of a new anionic cell‐penetrating peptide: SAP (E) | |
US8575305B2 (en) | Cell penetrating peptides | |
EP2951196B1 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
EP2928908B1 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
US20160115199A1 (en) | Cell Penetrating Peptides for Intracellular Delivery of Molecules | |
US9849190B2 (en) | Peptide having cancer selective translocation function and use thereof | |
Tomassi et al. | Cationic nucleopeptides as novel non-covalent carriers for the delivery of peptide nucleic acid (PNA) and RNA oligomers | |
Wang et al. | CPP2-p16MIS treatment–induced colon carcinoma cell death in vitro and prolonged lifespan of tumor-bearing mice | |
WO2022139070A1 (ko) | 신규한 세포 투과성 펩타이드 및 이의 용도 | |
WO2010053320A2 (ko) | 세포 내로 카고를 전달하는 방법 및 이를 위한 펩타이드 | |
Beerens | Intercellular spread of the transgene product to improve the efficiency of cancer gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080015434.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10743956 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/008727 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2753181 Country of ref document: CA Ref document number: 5995/CHENP/2011 Country of ref document: IN Ref document number: 2010743956 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13202317 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI1005822 Country of ref document: BR |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI1005822 Country of ref document: BR |